- Home
- AGIO vs CPRX Comparison
AGIO vs CPRX Comparison
Compare AGIO & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- CPRX
- Stock Information
- Founded
- AGIO 2007
- CPRX 2002
- Country
- AGIO United States
- CPRX United States
- Employees
- AGIO N/A
- CPRX N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- AGIO Health Care
- CPRX Health Care
- Exchange
- AGIO Nasdaq
- CPRX Nasdaq
- Market Cap
- AGIO 2.5B
- CPRX 2.8B
- IPO Year
- AGIO 2013
- CPRX 2006
- Fundamental
- Price
- AGIO $24.46
- CPRX $22.72
- Analyst Decision
- AGIO Buy
- CPRX Strong Buy
- Analyst Count
- AGIO 7
- CPRX 5
- Target Price
- AGIO $37.33
- CPRX $32.60
- AVG Volume (30 Days)
- AGIO 1.8M
- CPRX 1.4M
- Earning Date
- AGIO 10-30-2025
- CPRX 11-05-2025
- Dividend Yield
- AGIO N/A
- CPRX N/A
- EPS Growth
- AGIO N/A
- CPRX 44.94
- EPS
- AGIO N/A
- CPRX 1.71
- Revenue
- AGIO $44,791,000.00
- CPRX $578,196,000.00
- Revenue This Year
- AGIO $25.57
- CPRX $16.59
- Revenue Next Year
- AGIO $153.24
- CPRX $8.42
- P/E Ratio
- AGIO N/A
- CPRX $13.33
- Revenue Growth
- AGIO 36.26
- CPRX 25.56
- 52 Week Low
- AGIO $22.24
- CPRX $19.05
- 52 Week High
- AGIO $62.45
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- AGIO 25.59
- CPRX 61.89
- Support Level
- AGIO $22.24
- CPRX $22.23
- Resistance Level
- AGIO $46.00
- CPRX $23.11
- Average True Range (ATR)
- AGIO 2.20
- CPRX 0.90
- MACD
- AGIO -1.86
- CPRX 0.06
- Stochastic Oscillator
- AGIO 8.76
- CPRX 74.46
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).